BUPRENORPHINE SUMMARY
Buprenorphine hydrochloride sublingual tablets contains buprenorphine HCl.
Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor.
Buprenorphine is a Schedule III narcotic under the Controlled Substances Act.
Buprenorphine HCl sublingual tablets is indicated for the treatment of opioid dependence.
Â
|
|
NEWS HIGHLIGHTS
Published Studies Related to Buprenorphine
Neonatal outcomes and their relationship to maternal buprenorphine dose during
pregnancy. [2014]
neonatal clinical outcomes... CONCLUSIONS: (1) Findings failed to support the existence of a dose-response
A randomized, double-blind evaluation of buprenorphine taper duration in primary
prescription opioid abusers. [2013]
IMPORTANCE: Although abuse of prescription opioids (POs) is a significant public
health problem, few experimental studies have investigated the treatment needs of
this growing population. OBJECTIVE: To evaluate, following brief stabilization with a combination of
buprenorphine hydrochloride and naloxone hydrochloride dihydrate, the relative
efficacy of 1-, 2-, and 4-week buprenorphine tapering regimens and subsequent
naltrexone hydrochloride therapy in PO-dependent outpatients...
A randomised controlled trial of sublingual buprenorphine-naloxone film versus
tablets in the management of opioid dependence. [2013]
(substance use, psychosocial function)... CONCLUSIONS: The study demonstrated dose equivalence and comparable clinical
Cocaine use reduction with buprenorphine (CURB): rationale, design, and
methodology. [2013]
study... CONCLUSIONS: This research using 2 medications will demonstrate whether BUP,
Analgesia after feline ovariohysterectomy under midazolam-medetomidine-ketamine
anaesthesia with buprenorphine or butorphanol, and carprofen or meloxicam: a
prospective, randomised clinical trial. [2012]
One hundred female cats undergoing routine ovariohysterectomy under
midazolam-medetomidine-ketamine anaesthesia were included in a blinded,
randomised, prospective clinical study to compare postoperative analgesia
produced by four analgesic drug combinations given preoperatively (n = 25 per
group)...
Clinical Trials Related to Buprenorphine
Buprenorphine for the Treatment of Neonatal Abstinence Syndrome [Completed]
Neonatal abstinence syndrome is a disease that affects children who were exposed to opioid
drugs prior to birth. Commonly used treatments at present include morphine or tincture of
opium. Buprenorphine is a drug used in adults to treat narcotic dependence, but has not
been used for Neonatal Abstinence Syndrome. This trial is designed to see if the use of
sublingual (under the tongue) buprenorphine is able to be used safely and easily in newborns
with the neonatal abstinence syndrome. Secondary goals will be to see if treatment with
buprenorphine is associated shorter stays in the hospital and fewer days of treatment than
the use of standard therapy. Another secondary goal will be to understand buprenorphine
concentration in the blood of babies treated with the drug (this is called
"pharmacokinetics").
Disposition Effects of Cyclosporin on Buprenorphine [Recruiting]
The purpose of this study is to see how healthy volunteers bodies handle buprenorphine.
Preference for Subutex� (Buprenorphine) Versus Suboxone� (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex� (Study P05094)(COMPLETED) [Completed]
This study is designed to determine if opioid dependent subjects who are already receiving
Subutex® prefer the Suboxone® tablet over the Subutex® tablet after switching from Subutex®
to Suboxone®. Subjects who are selected to participate in this study will continue their
prescribed dose of Subutex® (buprenorphine 2 to 16 mg daily) for the first two days of the
study (Day 1 and Day 2) then switch to and receive an equivalent dose of Suboxone®
(buprenorphine 2 to 16 mg daily) for the last 3 days of the study (Day 3, Day 4 and Day 5).
The Day 5 Visit will be the subject's last study visit. Upon completing the study, subjects
will continue their pre-study prescribed dosage of Subutex®.
Buprenorphine Group Medical Visits in Primary Care [Not yet recruiting]
The primary goal of this research is to improve the effectiveness of buprenorphine
maintenance treatment (BMT) within primary care.
Investigators propose that providing BMT as part of a group medical visit (instead of an
individual visit) will improve treatment outcomes for patients with persistent opioid
abuse, because members become accountable to the group, are exposed to beneficial habits of
others (i. e. positive deviance), and can receive efficacious behavioral interventions
concomitantly with medical management
Integrating Buprenorphine Into the SFGH AIDS Program [Completed]
Reports of Suspected Buprenorphine Side Effects
Nausea (30),
Vomiting (27),
Maternal Exposure During Pregnancy (27),
Hyperhidrosis (24),
Dizziness (21),
Toxicity TO Various Agents (20),
Foetal Exposure During Pregnancy (19),
Disorientation (18),
Ataxia (17),
Somnolence (16), more >>
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Buprenorphine has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
| | Buprenorphine review by 36 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Highly Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | Major Depression |
| Dosage & duration: | | 8mg sublingual tablets taken 2 sublinguals twice/day for the period of still taking it - has been 4 years |
| Other conditions: | | Anorexia nervosa, PTSD (World Trade Center Survivor 9/11/01) |
| Other drugs taken: | | Effexor XR, Adderall | | |
Reported Results |
| Benefits: | | Subutex is mostly used to help opiate addicts withdrawal more comfortably from opiod drugs such as Vicodin, Oxycodone, and even Heroin. However, I was started on Subutex because my doctor and I were having no luck finding another med that would augment my current depression medications of Effexor XR and Adderall (which were only partially working). My doctor had found research suggesting that Subutex, because it is a partial opiate agonist itself (although much different in its properties compared to what most think of when thinking "opiate"), binds to one of the opiate receptors in the brain responsible for mood. My doctor has always been on the cutting edge of current research and was extremely open-minded in trying this med with me - and to welcomed relief as well! I have had almost ALL good results from this medication. It has definitely aided in the treatment of my very-treatment-resistent depression. The following are the benefits that I have noticed from taking Subutex:
1. Quick-acting - because Subutex is sublingual (dissolves under your tongue) it gets into your system immediately and does not have to be processed by your digestive system first.
2. Gentle effects - I have definitly not experienced any "highs". Just a subtle, but noticeable improvement in a feeling of wellbeing.
3. Also helps somewhat with anxiety by having a calming effect; in normal doses this happens without any tiredness.
4. Have not noticed ANY of the side effects that I have found with other psychiatric medications such as weight gain/loss, personality changes, sexual effects, etc. Also, in case anyone is worried that Subutex is a "partial-opiate agonist", I must emphasize that this med DOES NOT build a tolerance or make you want/need to increase dosage. I have been on this dose for four years without ever even thinking about needing more. HOWEVER!!! You must understand that - as is the case with ALL psychiatric medications - you cannot simply stop taking this medication without tapering your dose first or you will experience withdrawal effects. The one saving grace about Subutex, though, is that it has a very long half-life and will remain in your system long enough to prevent any type of withdrawal even if you miss a day or two of medication. |
| Side effects: | | None. |
| Comments: | | I take two 8mg tablets in the afternoon by putting them under my tongue and allowing them simply to dissolve. I do this again at night as I get into bed. That's pretty much it! |
|
|
|
Page last updated: 2014-11-30
|
